STOCK TITAN

Scilex Holding Co (SMNR) details 13.97M Semnur stock dividend and abeyance

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Scilex Holding Co, a major holder of Semnur Pharmaceuticals, Inc., reported a previously announced stock dividend of 13,972,900 shares of Semnur common stock distributed to its own common shareholders and certain warrant and convertible note holders as of a June 1, 2026 record date.

The filing notes that 6,938,163 of these dividend shares are being held in abeyance for additional participating warrant and note holders, to be distributed if and when those instruments are exercised or converted, with a separate Form 4 to be filed at that time. The report also shows a J-code restructuring entry for 7,034,737 Semnur common shares at a stated price of $0.0000 per share and updated direct and indirect ownership positions, including shares held through Scilex, Inc. and Scilex Bio, Inc.

Positive

  • None.

Negative

  • None.
Insider Scilex Holding Co, Scilex, Inc.
Role null | null
Type Security Shares Price Value
Other Common Stock 7,034,737 $0.00 --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 174,770,112 shares (Indirect, By Scilex, Inc.); Common Stock — 500,000 shares (Direct, null)
Footnotes (1)
  1. On June 15, 2026, the Reporting Person paid its previously announced stock dividend (the "Dividend") consisting of an aggregate of 13,972,900 shares of common stock of Semnur Pharmaceuticals, Inc. ("Semnur") held by the Reporting Person (the "Dividend Shares") to record holders of (i) the Reporting Person's common stock, (ii) certain warrants to purchase the Reporting Person's common stock and (iii) certain notes convertible into shares of the Reporting Person's common stock as of June 1, 2026 (the "Record Date" and the holders referenced in clauses (ii) and (iii), the "Additional Participating Holders"). An aggregate of 6,938,163 Dividend Shares are being held in abeyance by the Reporting Person for the benefit of the Additional Participating Holders who may be entitled to such shares pursuant to the terms of the applicable warrants and convertible notes following the exercise or conversion thereof, and at the time such shares are distributed to the applicable warrantholders and noteholders, the Reporting Person will file a Form 4 reporting such distribution.
Dividend shares 13,972,900 shares Aggregate Semnur common stock paid as stock dividend
Shares in abeyance 6,938,163 shares Dividend shares held for additional participating holders
J-code transaction size 7,034,737 shares Other acquisition or disposition of Semnur common stock
J-code stated price $0.0000 per share Stated transaction price for 7,034,737 Semnur shares
Indirect holding after J transaction 174,770,112 shares Semnur common stock held indirectly by Scilex, Inc.
Indirect holding via Scilex Bio, Inc. 6,250,000 shares Semnur common stock held indirectly
Direct holding 500,000 shares Semnur common stock held directly
stock dividend financial
"the Reporting Person paid its previously announced stock dividend (the "Dividend") consisting of an aggregate of 13,972,900 shares"
A stock dividend is when a company gives its existing shareholders extra shares instead of cash. It’s like receiving more pieces of the same pie rather than a bigger piece of money, which can increase the number of shares you own but usually doesn’t change the total value of your investment right away. Investors care about it because it can signal the company's growth and affect the stock’s price.
Record Date financial
"as of June 1, 2026 (the "Record Date" and the holders referenced"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
Additional Participating Holders financial
"the holders referenced in clauses (ii) and (iii), the "Additional Participating Holders")"
warrants financial
"certain warrants to purchase the Reporting Person's common stock and (iii) certain notes convertible"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
convertible notes financial
"and (iii) certain notes convertible into shares of the Reporting Person's common stock"
Convertible notes are a type of short-term loan that a company receives from investors, which can later be turned into company shares instead of being paid back in cash. They matter to investors because they offer a way to support a company early on while giving the potential to own a stake in its success if the company grows and later raises more funding.
held in abeyance financial
"An aggregate of 6,938,163 Dividend Shares are being held in abeyance by the Reporting Person"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Scilex Holding Co

(Last)(First)(Middle)
960 SAN ANTONIO RD

(Street)
PALO ALTO CALIFORNIA 94303

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Semnur Pharmaceuticals, Inc. [ SMNR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/15/2026J(1)(2)7,034,737(1)(2)D$0174,770,112IBy Scilex, Inc.
Common Stock500,000D
Common Stock6,250,000IBy Scilex Bio, Inc.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
Scilex Holding Co

(Last)(First)(Middle)
960 SAN ANTONIO RD

(Street)
PALO ALTO CALIFORNIA 94303

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Scilex, Inc.

(Last)(First)(Middle)
960 SAN ANTONIO RD

(Street)
PALO ALTO CALIFORNIA 94303

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. On June 15, 2026, the Reporting Person paid its previously announced stock dividend (the "Dividend") consisting of an aggregate of 13,972,900 shares of common stock of Semnur Pharmaceuticals, Inc. ("Semnur") held by the Reporting Person (the "Dividend Shares") to record holders of (i) the Reporting Person's common stock, (ii) certain warrants to purchase the Reporting Person's common stock and (iii) certain notes convertible into shares of the Reporting Person's common stock as of June 1, 2026 (the "Record Date" and the holders referenced in clauses (ii) and (iii), the "Additional Participating Holders").
2. An aggregate of 6,938,163 Dividend Shares are being held in abeyance by the Reporting Person for the benefit of the Additional Participating Holders who may be entitled to such shares pursuant to the terms of the applicable warrants and convertible notes following the exercise or conversion thereof, and at the time such shares are distributed to the applicable warrantholders and noteholders, the Reporting Person will file a Form 4 reporting such distribution.
/s/ Henry Ji, Scilex Holding Company, Chief Executive Officer, President and Chairperson06/26/2026
/s/ Henry Ji, Scilex, Inc., Chief Executive Officer and President06/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Scilex Holding Co disclose in this Form 4 for SMNR?

Scilex Holding Co disclosed a previously announced stock dividend of 13,972,900 Semnur Pharmaceuticals (SMNR) common shares. These shares were distributed to Scilex common shareholders and certain warrant and note holders as of a June 1, 2026 record date.

How many Semnur (SMNR) shares are held in abeyance for additional holders?

An aggregate 6,938,163 Semnur (SMNR) dividend shares are being held in abeyance for certain warrant and convertible note holders. These may later be distributed if those instruments are exercised or converted, and such distributions will be reported in a future Form 4.

What does the J-code transaction in the SMNR Form 4 represent?

The Form 4 shows a J-code transaction involving 7,034,737 shares of Semnur (SMNR) common stock at a stated price of $0.0000 per share. J-code entries reflect "other" transactions, often internal restructurings, rather than open-market buys or sells.

Who benefits from the Semnur (SMNR) stock dividend reported by Scilex?

The Semnur (SMNR) stock dividend benefits record holders of Scilex common stock, and certain warrant and convertible note holders, as of June 1, 2026. Additional participating warrant and note holders may receive shares later as their instruments are exercised or converted.